REACH and CLP Rules for Research Chemicals in the EU

A gram of a catalogue substance can pass through three jurisdictions before it reaches a bench, and the paperwork travelling with it changes at each border. The REACH and CLP rules for research chemicals set the European baseline — what has to be registered, how a container must be classified and labelled, what a supplier must hand to the recipient. They do not settle everything. National law still decides whether a particular compound may be placed on the market at all, and in which language the label has to be printed.

This article is a map of that framework: which regulation does what, where the thresholds sit, and which differences between Member States are real rather than rumoured. It describes legal structures. It does not advise on how to work around any of them.

REACH and CLP rules that apply to research chemicals in the EU

Two regulations carry most of the weight. REACH is Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals, establishing a European Chemicals Agency. CLP is Regulation (EC) No 1272/2008 of 16 December 2008 on classification, labelling and packaging of substances and mixtures.

They answer different questions. REACH asks who put the substance on the European market, in what quantity, and what they know about it. CLP asks what the hazard of that substance is, and how that hazard must be communicated on the container.

Question	REACH (1907/2006)	CLP (1272/2008)
Core duty	Register substances manufactured or imported at one tonne or more per year (Article 6(1))	Classify substances or mixtures before placing them on the market (Article 4(1))
Trigger	Tonnage per manufacturer or importer per year	Placing on the market, with no tonnage trigger in Article 4(1)
Main document	Safety data sheet under Article 31 and Annex II	Label under Article 17, plus notification to the Agency under Article 40
Language rule	Safety data sheet in an official language of the Member State where the substance is placed on the market (Article 31(5))	Label in the official language(s) of that Member State (Article 17(2))
Central database	Registration dossiers held by the Agency	Classification and labelling inventory (Article 42)

The notification duty under CLP Article 40 falls on any manufacturer or importer, or group of them, who places a relevant substance on the market. What they notify includes the identity of the notifier and of the substance, and the classification. That is how the classification and labelling inventory gets populated — not by a regulator testing samples, but by industry declaring its own classifications.

One consequence follows directly. CLP Article 41 allows manufacturers and importers to classify a substance differently from an entry already in the inventory, provided they submit their reasons to the Agency with the notification. That does not apply where the entry is a harmonised classification in Part 3 of Annex VI. So for most substances, two suppliers can legitimately disagree about the hazard classification, and both entries sit in the same public inventory.

What the one tonne per year registration threshold actually means

REACH Article 6(1) is short: “Save where this Regulation provides otherwise, any manufacturer or importer of a substance, either on its own or in one or more preparation(s), in quantities of one tonne or more per year shall submit a registration to the Agency.” A submission must be accompanied by a fee under Title IX.

Read it carefully, because three details are routinely misread.

The threshold is per legal entity, per year. It is not a property of the substance. The same compound can be registered by a bulk manufacturer and simultaneously be below threshold for a small importer.
It attaches to manufacture or import into the EU, not to resale within it. A distributor buying registered material inside the Union is not the registrant.
Below one tonne, there is no registration dossier at all. Most catalogue substances sold in gram quantities never come close. Annex II requires that, for substances subject to registration, the registration number assigned under Article 20(3) be given in section 1.1 of the safety data sheet. Where there is no registration, there is no number to print, and its absence is not by itself evidence of a bad supplier.

REACH also defines the research case explicitly. “Scientific research and development” means, in Article 3, “any scientific experimentation, analysis or chemical research carried out under controlled conditions in a volume less than one tonne per year”. Two further provisions hang on that definition: Article 56(3) disapplies the authorisation requirement to the use of substances in scientific research and development, and Article 67(1) states that the Annex XVII restriction rule does not apply to manufacture, placing on the market or use of a substance in scientific research and development.

None of this is a general exemption from chemical law. The CLP duty to classify in Article 4(1) carries no tonnage threshold at all, and the safety data sheet duty in Article 31(1) is triggered by hazard, by persistent, bioaccumulative and toxic or very persistent and very bioaccumulative properties, or by inclusion in the candidate list under Article 59(1) — never by tonnage.

Why the same substance ships with a different safety data sheet in Germany and Poland

A safety data sheet is not a fixed international text. Annex II to REACH, as replaced by Commission Regulation (EU) 2020/878 of 18 June 2020, sets sixteen numbered sections, and at least two of them are country-specific by design.

Section 8.1.1 requires that, where available, national limit values currently applicable in the Member State in which the safety data sheet is being provided be listed, including the legal basis of each. The Annex spells out the categories: national occupational exposure limit values corresponding to Union values under Directive 98/24/EC, those corresponding to Union limit values under Directive 2004/37/EC, any other national occupational exposure limit values, and the equivalent national biological limit values.

Section 8 of a German sheet and a Polish sheet for the same substance can therefore both be correct and still not match. The difference is not sloppiness. It is the regulation working as written.

Article 31(5) adds the second divergence: the sheet must be supplied in an official language of the Member State where the substance is placed on the market, unless that Member State provides otherwise. A supplier serving seven countries maintains seven language versions of a living document.

Dates matter too. Regulation (EU) 2020/878 applies from 1 January 2021, and by derogation, sheets not complying with its Annex could continue to be provided until 31 December 2022. A sheet still carrying the older format is a signal about the supplier’s document maintenance, not a legal impossibility in every historical context. Annex II requires the date of compilation on the first page, and for revised sheets a “Revision: (date)” marking plus an indication of which version is superseded. Those two fields are the cheapest quality check available to a buyer.

Annex II also forbids a class of reassuring language outright. Statements such as “may be dangerous”, “no health effects”, “safe under most conditions of use” or “harmless” must not be used, nor any statement inconsistent with the classification. A sheet containing them is defective on its face.

Why a substance can be legal in one EU country and controlled in another

REACH and CLP harmonise chemical safety duties. They do not harmonise controlled-substance law, which sits in a different legal family and moves at a different speed.

At Union level, Directive (EU) 2017/2103 of 15 November 2017 amended Council Framework Decision 2004/757/JHA in order to include new psychoactive substances in the definition of ‘drug’, and repealed Council Decision 2005/387/JHA. That instrument sets a common floor. It does not replace national criminal law.

A 2020 review in International Journal of Environmental Research and Public Health documents how far national approaches diverge in practice. Consumer safety and medicines legislation have been used as control routes: some consumer protection laws targeted psychoactive products in general, while others addressed single substances. Eight countries used medicines law to control the distribution of new psychoactive substances, requiring national authorisation for importation, supply or sale — an approach the review reports was narrowed in July 2014, when the Court of Justice of the European Union ruled that substances are not medicinal products if they do not have beneficial effects on human health.

Where countries wrote dedicated legislation, the definitions themselves differ. The same review records that Ireland, Austria, Portugal, Romania, Sweden and the United Kingdom each enacted new law, and that most defined a psychoactive substance as a stimulant or depressant of the central nervous system, while the United Kingdom tied “psychoactive” to alteration of a person’s mental or emotional state. In Ireland, Romania and the United Kingdom, substances meeting the statutory characteristics were covered without being named; in Austria, substances had to be named by the Minister of Health. Maximum penalties for supply differed across those systems.

National risk assessment practice varies as well. The review cites an earlier survey of twenty-six countries in which six ran no national risk assessment and relied on international or European assessments, seven ran one only where necessary, and thirteen ran one as part of deciding whether to control a substance.

The operational consequence is blunt and worth stating plainly: legality in the supplier’s country tells you nothing about legality in yours. The controlling law is the law of the destination and of the institution receiving the material. That is a question for the recipient’s legal or compliance function before an order is placed, not a question a catalogue can answer. Nonsensia’s own terms of supply require the buyer to confirm research use and to be responsible for compliance in their own jurisdiction.

What paperwork should arrive with a laboratory order

Four documents commonly travel with a shipment, and only some of them are required by the regulations discussed above.

Document	Who produces it	What it establishes	Legal basis
Safety data sheet	Supplier	Hazards, handling, storage, disposal, national exposure limits, regulatory status	REACH Article 31 and Annex II
Container label	Supplier	Product identifier, hazard pictograms, signal word, hazard and precautionary statements, supplier contact	CLP Articles 17 and 18
Certificate of analysis	Supplier or contract laboratory	Identity and purity of the specific batch by named analytical methods	Commercial and quality-system document; not one of the documents named in REACH Article 31
End-use declaration	Buyer	That the material is ordered for laboratory and research use, excluding human use	Supplier’s terms of supply

The distinction in the third row is the one most often lost. A certificate of analysis is a quality document, and the regulation that names it is the supplier’s own quality system rather than REACH. That is precisely why its content varies so much between vendors, and why a certificate naming the method, the batch and the date of analysis is worth more than one carrying a bare percentage.

Small containers have their own labelling rule. CLP Article 29(1) covers the case where packaging is so small or so shaped that the full label cannot be applied in the required languages; the label elements may then be provided on fold-out labels, tie-on tags or outer packaging, and Annex I section 1.5.1.2 requires the inner packaging to carry at least the hazard pictograms, the product identifier and the supplier’s name and telephone number. Annex I section 1.5.2.1 sets a further, explicitly numbered case: packages whose contents do not exceed 125 ml, where certain hazard and precautionary statements may be omitted for the listed hazard categories. A milligram-scale vial bearing a reduced label is therefore not automatically an under-labelled one.

Where price differences in the research chemical market come from

Two suppliers quoting the same nominal purity for the same substance can differ several-fold in price. The verifiable drivers are structural rather than mysterious.

Registration and notification burden. A registration under REACH Article 6 carries a fee under Title IX. A CLP Article 40 notification carries administrative work per substance.
Documentation maintenance. Annex II requires that the safety data sheet be prepared by a competent person, and that suppliers ensure such persons receive appropriate training, including refresher training. Multiply that by Article 31(5) language versions and Article 17(2) label versions.
Emergency-response infrastructure. Under CLP Article 45, Member States appoint bodies to receive composition information for mixtures placed on the market, which those bodies must hold in confidence.
Analytical characterisation. Identity confirmation and batch purity testing are real laboratory hours, and a certificate reporting several orthogonal methods costs more to produce than one reporting a single chromatographic number.
Packaging at small scale. Dispensing and labelling gram or sub-gram units carries a fixed cost that does not scale down with quantity.

What price does not tell you is purity. Purity is a measured property of a batch, reported with a method and a date; price is a commercial decision. The two correlate loosely at best, and treating a high price as a purity claim is a category error.

Frequently asked questions

What is the difference between REACH and CLP?

REACH, Regulation (EC) No 1907/2006, governs registration of substances manufactured or imported at one tonne or more per year and requires safety data sheets under Article 31. CLP, Regulation (EC) No 1272/2008, governs how substances are classified, labelled and packaged, and requires notification of classifications to the European Chemicals Agency under Article 40. One tracks who supplies what; the other tracks what the hazard is.

Does a research chemical need REACH registration?

Only if a single manufacturer or importer places one tonne or more of it on the EU market per year, which Article 6(1) sets as the threshold. Substances sold in gram quantities normally fall far below it, so no registration dossier exists and no registration number appears in section 1.1 of the safety data sheet. Classification and labelling duties under CLP still apply regardless of tonnage.

Why do safety data sheets differ between EU countries?

Because Annex II to REACH requires it. Section 8.1.1 requires national occupational and biological limit values applicable in the Member State where the sheet is provided, with their legal basis. Article 31(5) requires the sheet in an official language of that Member State. Two sheets for the same substance in two countries can therefore both be compliant and still differ in content.

Is a certificate of analysis a legal requirement in the EU?

It is not among the documents REACH Article 31 requires a supplier to provide; that article names the safety data sheet. A certificate of analysis is a quality document produced under the supplier’s own system, which is why its scope varies. Useful certificates identify the batch, the analytical methods used and the date of analysis rather than stating a bare purity figure.

Why is a substance legal in one EU country and controlled in another?

Controlled-substance law is national. Directive (EU) 2017/2103 brought new psychoactive substances into the EU definition of ‘drug’, but Member States have used consumer safety law, medicines law and dedicated national statutes with differing definitions and penalties. Legality in a supplier’s country carries no weight in the destination country; that question belongs to the recipient’s legal or compliance function.

Who has to notify a classification to ECHA?

Under CLP Article 40, any manufacturer or importer, or group of manufacturers or importers, placing a substance covered by Article 39 on the market must notify the Agency. The notification includes the identity of the notifier, the identity of the substance and its classification. Those notifications populate the public classification and labelling inventory established under Article 42.

Can two suppliers classify the same substance differently?

Yes, within limits. CLP Article 41 permits a manufacturer or importer to classify a substance differently from an existing inventory entry if they submit their reasons to the Agency with the notification. That permission does not extend to substances with a harmonised classification in Part 3 of Annex VI, where the harmonised entry governs.

What language must a chemical label be written in?

CLP Article 17(2) requires the label to be written in the official language or languages of the Member State where the substance or mixture is placed on the market, unless that Member State provides otherwise. Where the package is too small for a compliant label, Article 29(1) and Annex I section 1.5.1 allow fold-out labels, tie-on tags or outer packaging instead.

References

Research use only. Nonsensia Lab supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.

Filed under: Industry & Market

Nonsensia Lab supplies the compounds discussed in this guide as analytical reference standards for laboratory and research use.

How the Research Chemicals Market Works: Regulation, Supply and Quality